Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy
- 1 September 1990
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 336 (8715), 585-590
- https://doi.org/10.1016/0140-6736(90)93391-2
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Long-term zidovudine treatment of asymptomatic HIV-1-infected subjectsAntiviral Research, 1990
- Quantitation of Human Immunodeficiency Virus Type 1 in the Blood of Infected PersonsNew England Journal of Medicine, 1989
- Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)Science, 1989
- Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working GroupPublished by American Medical Association (AMA) ,1989
- HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged TherapyScience, 1989
- Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea programJAMA, 1988
- Numbers of CD4+ Cells and the Levels of Core Antigens of and Antibodies to the Human Immunodeficiency Virus as Predictors of AIDS Among Seropositive Homosexual MenThe Journal of Infectious Diseases, 1988
- EFFECT OF ZIDOVUDINE ON SERUM HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN LEVELS IN SYMPTOM-FREE SUBJECTSThe Lancet, 1988
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.BMJ, 1986